Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study

Eric Hollander, Nicolò Baldini Rossi, Erica Sood, Stefano Pallanti

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease ≥5%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.

Original languageEnglish (US)
Pages (from-to)397-401
Number of pages5
JournalInternational Journal of Neuropsychopharmacology
Volume6
Issue number4
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Risperidone
Obsessive-Compulsive Disorder
Placebos
Serotonin Uptake Inhibitors
Therapeutics
Sample Size

Keywords

  • Compulsions
  • Obsessions
  • Obsessive-compulsive disorder
  • Risperidone
  • Treatment resistant

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder : A double-blind, placebo-controlled study. / Hollander, Eric; Rossi, Nicolò Baldini; Sood, Erica; Pallanti, Stefano.

In: International Journal of Neuropsychopharmacology, Vol. 6, No. 4, 12.2003, p. 397-401.

Research output: Contribution to journalArticle

@article{977f5217b313479fb0dd69db4b3502e0,
title = "Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study",
abstract = "This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40{\%}) and none (0{\%}) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease ≥5{\%}. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.",
keywords = "Compulsions, Obsessions, Obsessive-compulsive disorder, Risperidone, Treatment resistant",
author = "Eric Hollander and Rossi, {Nicol{\`o} Baldini} and Erica Sood and Stefano Pallanti",
year = "2003",
month = "12",
doi = "10.1017/S1461145703003730",
language = "English (US)",
volume = "6",
pages = "397--401",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "4",

}

TY - JOUR

T1 - Risperidone augmentation in treatment-resistant obsessive-compulsive disorder

T2 - A double-blind, placebo-controlled study

AU - Hollander, Eric

AU - Rossi, Nicolò Baldini

AU - Sood, Erica

AU - Pallanti, Stefano

PY - 2003/12

Y1 - 2003/12

N2 - This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease ≥5%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.

AB - This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease ≥5%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.

KW - Compulsions

KW - Obsessions

KW - Obsessive-compulsive disorder

KW - Risperidone

KW - Treatment resistant

UR - http://www.scopus.com/inward/record.url?scp=0742270813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742270813&partnerID=8YFLogxK

U2 - 10.1017/S1461145703003730

DO - 10.1017/S1461145703003730

M3 - Article

C2 - 14604454

AN - SCOPUS:0742270813

VL - 6

SP - 397

EP - 401

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 4

ER -